Prior outlook $3.07B-$3.12B. Consensus $3.10B. Sees 2025 adjusted EBITDA $455M-$475M vs. prior $425M-$455M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences reports Q2 EPS (1c), consensus (15c)
- Exact Sciences’ Growth Potential Bolstered by Cologuard Plus and Strategic Medicare Advantage Agreement
- EXAS Upcoming Earnings Report: What to Expect?
- Exact Sciences expands colorectal cancer screening partnership with Humana
- Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook